Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Hitting HIV's Harpoon.

van Gils MJ, Sanders RW.

Immunity. 2018 Jul 17;49(1):14-15. doi: 10.1016/j.immuni.2018.07.003.

PMID:
30021141
2.

Short Communication: Protective Efficacy of Broadly Neutralizing Antibody PGDM1400 Against HIV-1 Challenge in Humanized Mice.

van der Velden YU, Villaudy J, Siteur-van Rijnstra E, van der Linden CA, Frankin E, Weijer K, Schermer E, Vink MA, Berkhout B, Sanders RW, van Gils MJ.

AIDS Res Hum Retroviruses. 2018 Sep;34(9):790-793. doi: 10.1089/AID.2018.0114. Epub 2018 Aug 22.

PMID:
30003812
3.

Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.

Klasse PJ, Ketas TJ, Cottrell CA, Ozorowski G, Debnath G, Camara D, Francomano E, Pugach P, Ringe RP, LaBranche CC, van Gils MJ, Bricault CA, Barouch DH, Crotty S, Silvestri G, Kasturi S, Pulendran B, Wilson IA, Montefiori DC, Sanders RW, Ward AB, Moore JP.

PLoS Pathog. 2018 Feb 23;14(2):e1006913. doi: 10.1371/journal.ppat.1006913. eCollection 2018 Feb.

4.

Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers.

de Taeye SW, de la Peña AT, Vecchione A, Scutigliani E, Sliepen K, Burger JA, van der Woude P, Schorcht A, Schermer EE, van Gils MJ, LaBranche CC, Montefiori DC, Wilson IA, Moore JP, Ward AB, Sanders RW.

J Biol Chem. 2018 Feb 2;293(5):1688-1701. doi: 10.1074/jbc.RA117.000709. Epub 2017 Dec 8.

5.

Opposites attract in bispecific antibody engineering.

van Gils MJ, Sanders RW.

J Biol Chem. 2017 Sep 1;292(35):14718-14719. doi: 10.1074/jbc.H117.793497.

6.

Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization.

Torrents de la Peña A, Julien JP, de Taeye SW, Garces F, Guttman M, Ozorowski G, Pritchard LK, Behrens AJ, Go EP, Burger JA, Schermer EE, Sliepen K, Ketas TJ, Pugach P, Yasmeen A, Cottrell CA, Torres JL, Vavourakis CD, van Gils MJ, LaBranche C, Montefiori DC, Desaire H, Crispin M, Klasse PJ, Lee KK, Moore JP, Ward AB, Wilson IA, Sanders RW.

Cell Rep. 2017 Aug 22;20(8):1805-1817. doi: 10.1016/j.celrep.2017.07.077.

7.

Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.

Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H, Cesar Lorenzi JC, Halper-Stromberg A, Toth I, Piechocka-Trocha A, Gristick HB, van Gils MJ, Sanders RW, Wang LX, Seaman MS, Burton DR, Gazumyan A, Walker BD, West AP Jr, Bjorkman PJ, Nussenzweig MC.

Sci Transl Med. 2017 Jan 18;9(373). pii: eaal2144. doi: 10.1126/scitranslmed.aal2144.

8.

Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer.

Havenar-Daughton C, Carnathan DG, Torrents de la Peña A, Pauthner M, Briney B, Reiss SM, Wood JS, Kaushik K, van Gils MJ, Rosales SL, van der Woude P, Locci M, Le KM, de Taeye SW, Sok D, Mohammed AUR, Huang J, Gumber S, Garcia A, Kasturi SP, Pulendran B, Moore JP, Ahmed R, Seumois G, Burton DR, Sanders RW, Silvestri G, Crotty S.

Cell Rep. 2016 Nov 22;17(9):2195-2209. doi: 10.1016/j.celrep.2016.10.085.

9.

An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability.

van Gils MJ, van den Kerkhof TL, Ozorowski G, Cottrell CA, Sok D, Pauthner M, Pallesen J, de Val N, Yasmeen A, de Taeye SW, Schorcht A, Gumbs S, Johanna I, Saye-Francisco K, Liang CH, Landais E, Nie X, Pritchard LK, Crispin M, Kelsoe G, Wilson IA, Schuitemaker H, Klasse PJ, Moore JP, Burton DR, Ward AB, Sanders RW.

Nat Microbiol. 2016 Nov 14;2:16199. doi: 10.1038/nmicrobiol.2016.199.

10.

Natural infection as a blueprint for rational HIV vaccine design.

van Haaren MM, van den Kerkhof TL, van Gils MJ.

Hum Vaccin Immunother. 2017 Jan 2;13(1):229-236. doi: 10.1080/21645515.2016.1232785. Epub 2016 Sep 20. Review.

11.

Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C.

Klasse PJ, LaBranche CC, Ketas TJ, Ozorowski G, Cupo A, Pugach P, Ringe RP, Golabek M, van Gils MJ, Guttman M, Lee KK, Wilson IA, Butera ST, Ward AB, Montefiori DC, Sanders RW, Moore JP.

PLoS Pathog. 2016 Sep 14;12(9):e1005864. doi: 10.1371/journal.ppat.1005864. eCollection 2016 Sep.

12.

Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies.

McCoy LE, van Gils MJ, Ozorowski G, Messmer T, Briney B, Voss JE, Kulp DW, Macauley MS, Sok D, Pauthner M, Menis S, Cottrell CA, Torres JL, Hsueh J, Schief WR, Wilson IA, Ward AB, Sanders RW, Burton DR.

Cell Rep. 2016 Aug 30;16(9):2327-38. doi: 10.1016/j.celrep.2016.07.074. Epub 2016 Aug 18.

13.

HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds.

van den Kerkhof TL, de Taeye SW, Boeser-Nunnink BD, Burton DR, Kootstra NA, Schuitemaker H, Sanders RW, van Gils MJ.

Retrovirology. 2016 Jul 7;13(1):48. doi: 10.1186/s12977-016-0279-4.

14.

Probability of N332 glycan occupancy on HIV-1 gp120 modulates sensitivity to broadly neutralizing antibodies.

van den Kerkhof TL, van Gils MJ, Boeser-Nunnink BD, Burger JA, Schuitemaker H, Sanders RW.

AIDS. 2016 Sep 10;30(14):2179-84. doi: 10.1097/QAD.0000000000001177.

PMID:
27258397
15.

The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype.

Cornelissen M, Euler Z, van den Kerkhof TL, van Gils MJ, Boeser-Nunnink BD, Kootstra NA, Zorgdrager F, Schuitemaker H, Prins JM, Sanders RW, van der Kuyl AC.

AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):1135-1142. Epub 2016 Feb 24.

PMID:
26910384
16.

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies.

McCoy LE, Falkowska E, Doores KJ, Le K, Sok D, van Gils MJ, Euler Z, Burger JA, Seaman MS, Sanders RW, Schuitemaker H, Poignard P, Wrin T, Burton DR.

PLoS Pathog. 2015 Aug 12;11(8):e1005110. doi: 10.1371/journal.ppat.1005110. eCollection 2015 Aug.

17.

Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.

Hu JK, Crampton JC, Cupo A, Ketas T, van Gils MJ, Sliepen K, de Taeye SW, Sok D, Ozorowski G, Deresa I, Stanfield R, Ward AB, Burton DR, Klasse PJ, Sanders RW, Moore JP, Crotty S.

J Virol. 2015 Oct;89(20):10383-98. doi: 10.1128/JVI.01653-15. Epub 2015 Aug 5.

18.

Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice.

Dosenovic P, von Boehmer L, Escolano A, Jardine J, Freund NT, Gitlin AD, McGuire AT, Kulp DW, Oliveira T, Scharf L, Pietzsch J, Gray MD, Cupo A, van Gils MJ, Yao KH, Liu C, Gazumyan A, Seaman MS, Björkman PJ, Sanders RW, Moore JP, Stamatatos L, Schief WR, Nussenzweig MC.

Cell. 2015 Jun 18;161(7):1505-15. doi: 10.1016/j.cell.2015.06.003.

19.

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.

Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L, Arendt H, Kim HJ, Lee JH, Pugach P, Williams M, Debnath G, Moldt B, van Breemen MJ, Isik G, Medina-Ramírez M, Back JW, Koff WC, Julien JP, Rakasz EG, Seaman MS, Guttman M, Lee KK, Klasse PJ, LaBranche C, Schief WR, Wilson IA, Overbaugh J, Burton DR, Ward AB, Montefiori DC, Dean H, Moore JP.

Science. 2015 Jul 10;349(6244):aac4223. doi: 10.1126/science.aac4223. Epub 2015 Jun 18.

20.

Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex.

Sok D, van Gils MJ, Pauthner M, Julien JP, Saye-Francisco KL, Hsueh J, Briney B, Lee JH, Le KM, Lee PS, Hua Y, Seaman MS, Moore JP, Ward AB, Wilson IA, Sanders RW, Burton DR.

Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17624-9. doi: 10.1073/pnas.1415789111. Epub 2014 Nov 24.

21.

Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.

Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, Imamichi H, Georgiev IS, Chuang GY, Druz A, Doria-Rose NA, Laub L, Sliepen K, van Gils MJ, de la Peña AT, Derking R, Klasse PJ, Migueles SA, Bailer RT, Alam M, Pugach P, Haynes BF, Wyatt RT, Sanders RW, Binley JM, Ward AB, Mascola JR, Kwong PD, Connors M.

Nature. 2014 Nov 6;515(7525):138-42. doi: 10.1038/nature13601. Epub 2014 Sep 3.

22.

In vivo protection by broadly neutralizing HIV antibodies.

van Gils MJ, Sanders RW.

Trends Microbiol. 2014 Oct;22(10):550-1. doi: 10.1016/j.tim.2014.08.006. Epub 2014 Aug 26.

PMID:
25169020
23.

Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.

Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, Ramirez A, Derking R, van Gils MJ, Liang CH, Mcbride R, von Bredow B, Shivatare SS, Wu CY, Chan-Hui PY, Liu Y, Feizi T, Zwick MB, Koff WC, Seaman MS, Swiderek K, Moore JP, Evans D, Paulson JC, Wong CH, Ward AB, Wilson IA, Sanders RW, Poignard P, Burton DR.

Immunity. 2014 May 15;40(5):657-68. doi: 10.1016/j.immuni.2014.04.009. Epub 2014 Apr 24.

24.

Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers.

van den Kerkhof TL, Euler Z, van Gils MJ, Boeser-Nunnink BD, Schuitemaker H, Sanders RW.

AIDS. 2014 May 15;28(8):1237-40. doi: 10.1097/QAD.0000000000000228.

PMID:
24556870
25.

A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Peña AT, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, van Gils MJ, King CR, Wilson IA, Ward AB, Klasse PJ, Moore JP.

PLoS Pathog. 2013 Sep;9(9):e1003618. doi: 10.1371/journal.ppat.1003618. Epub 2013 Sep 19.

26.

HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.

van den Kerkhof TL, Feenstra KA, Euler Z, van Gils MJ, Rijsdijk LW, Boeser-Nunnink BD, Heringa J, Schuitemaker H, Sanders RW.

Retrovirology. 2013 Sep 23;10:102. doi: 10.1186/1742-4690-10-102.

27.

HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans.

Malherbe DC, Sanders RW, van Gils MJ, Park B, Gomes MM, Schuitemaker H, Barnett S, Haigwood NL.

PLoS One. 2013 Sep 9;8(9):e75277. doi: 10.1371/journal.pone.0075277. eCollection 2013.

28.

Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals.

Euler Z, van Gils MJ, Boeser-Nunnink BD, Schuitemaker H, van Manen D.

PLoS One. 2013;8(1):e54684. doi: 10.1371/journal.pone.0054684. Epub 2013 Jan 23.

29.

Determinants of calcification growth in atherosclerotic carotid arteries; a serial multi-detector CT angiography study.

van Gils MJ, Bodde MC, Cremers LG, Dippel DW, van der Lugt A.

Atherosclerosis. 2013 Mar;227(1):95-9. doi: 10.1016/j.atherosclerosis.2012.12.017. Epub 2012 Dec 24.

30.

Broadly neutralizing antibodies against HIV-1: templates for a vaccine.

van Gils MJ, Sanders RW.

Virology. 2013 Jan 5;435(1):46-56. doi: 10.1016/j.virol.2012.10.004. Review.

31.

Carotid atherosclerotic plaque progression and change in plaque composition over time: a 5-year follow-up study using serial CT angiography.

van Gils MJ, Vukadinovic D, van Dijk AC, Dippel DW, Niessen WJ, van der Lugt A.

AJNR Am J Neuroradiol. 2012 Aug;33(7):1267-73. doi: 10.3174/ajnr.A2970. Epub 2012 Feb 16.

32.

A personalized approach for predicting the effect of aerobic exercise on blood pressure using a Fuzzy Inference System.

Honka AM, van Gils MJ, Pärkkä J.

Conf Proc IEEE Eng Med Biol Soc. 2011;2011:8299-302. doi: 10.1109/IEMBS.2011.6092046.

PMID:
22256270
33.

Spectral entropy as a measure of hypnosis and hypnotic drug effect of total intravenous anesthesia in children during slow induction and maintenance.

Klockars JG, Hiller A, Münte S, van Gils MJ, Taivainen T.

Anesthesiology. 2012 Feb;116(2):340-51. doi: 10.1097/ALN.0b013e3182410b5e.

PMID:
22166950
34.

Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity.

Euler Z, van den Kerkhof TL, van Gils MJ, Burger JA, Edo-Matas D, Phung P, Wrin T, Schuitemaker H.

J Virol. 2012 Feb;86(4):2045-55. doi: 10.1128/JVI.06091-11. Epub 2011 Dec 7.

35.

Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum.

van Gils MJ, Edo-Matas D, Bowles EJ, Burger JA, Stewart-Jones GB, Schuitemaker H.

J Virol. 2011 Aug;85(16):8443-8. doi: 10.1128/JVI.05214-11. Epub 2011 Jun 8.

36.

Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies.

van Gils MJ, Bunnik EM, Boeser-Nunnink BD, Burger JA, Terlouw-Klein M, Verwer N, Schuitemaker H.

J Virol. 2011 Jul;85(14):6986-95. doi: 10.1128/JVI.00268-11. Epub 2011 May 18.

37.

Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010.

Brinckmann S, da Costa K, van Gils MJ, Hallengärd D, Klein K, Madeira L, Mainetti L, Palma P, Raue K, Reinhart D, Reudelsterz M, Ruffin N, Seifried J, Schäfer K, Sheik-Khalil E, Sköld A, Uchtenhagen H, Vabret N, Ziglio S, Scarlatti G, Shattock R, Wahren B, Gotch F.

J Transl Med. 2011 Apr 12;9:40. doi: 10.1186/1479-5876-9-40.

38.

Association between carotid artery plaque ulceration and plaque composition evaluated with multidetector CT angiography.

Homburg PJ, Rozie S, van Gils MJ, van den Bouwhuijsen QJ, Niessen WJ, Dippel DW, van der Lugt A.

Stroke. 2011 Feb;42(2):367-72. doi: 10.1161/STROKEAHA.110.597369. Epub 2010 Dec 23.

PMID:
21183745
39.

Evolution of atherosclerotic carotid plaque morphology: do ulcerated plaques heal? A serial multidetector CT angiography study.

van Gils MJ, Homburg PJ, Rozie S, de Weert TT, Dippel DW, van der Lugt A.

Cerebrovasc Dis. 2011;31(3):263-70. doi: 10.1159/000322152. Epub 2010 Dec 21.

PMID:
21178351
40.
41.

Increased variation of the response index of nociception during noxious stimulation in patients during general anaesthesia.

Sarén-Koivuniemi TJ, Yli-Hankala AM, van Gils MJ.

Comput Methods Programs Biomed. 2011 Nov;104(2):154-60. doi: 10.1016/j.cmpb.2010.10.001. Epub 2010 Oct 30.

PMID:
21036414
42.

Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference.

Wahren B, Biswas P, Borggren M, Coleman A, Da Costa K, De Haes W, Dieltjens T, Dispinseri S, Grupping K, Hallengärd D, Hornig J, Klein K, Mainetti L, Palma P, Reudelsterz M, Seifried J, Selhorst P, Sköld A, Uchtenhagen H, van Gils MJ, Weber C, Shattock R, Scarlatti G.

J Transl Med. 2010 Jul 26;8:72. doi: 10.1186/1479-5876-8-72. Erratum in: J Transl Med. 2010;8(1):82. Uchtenhagen, Hannes [added].

43.

Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection.

Edo-Matas D, van Gils MJ, Bowles EJ, Navis M, Rachinger A, Boeser-Nunnink B, Stewart-Jones GB, Kootstra NA, van 't Wout AB, Schuitemaker H.

Virology. 2010 Sep 30;405(2):492-504. doi: 10.1016/j.virol.2010.06.029. Epub 2010 Jul 17.

44.

Atherosclerotic plaque ulceration in the symptomatic internal carotid artery is associated with nonlacunar ischemic stroke.

Homburg PJ, Rozie S, van Gils MJ, Jansen T, de Weert TT, Dippel DW, van der Lugt A.

Stroke. 2010 Jun;41(6):1151-6. doi: 10.1161/STROKEAHA.109.576256. Epub 2010 Apr 22.

PMID:
20413739
45.

Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.

Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, Schuitemaker H.

J Infect Dis. 2010 Apr 1;201(7):1045-53. doi: 10.1086/651144.

PMID:
20170371
46.

Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors.

van Gils MJ, Bunnik EM, Burger JA, Jacob Y, Schweighardt B, Wrin T, Schuitemaker H.

J Virol. 2010 Apr;84(7):3576-85. doi: 10.1128/JVI.02622-09. Epub 2010 Jan 13.

47.

Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.

Bunnik EM, van Gils MJ, Lobbrecht MS, Pisas L, Nanlohy NM, van Baarle D, van Nuenen AC, Hessell AJ, Schuitemaker H.

J Gen Virol. 2010 May;91(Pt 5):1354-64. doi: 10.1099/vir.0.017319-0. Epub 2010 Jan 6.

PMID:
20053822
49.

Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.

van Gils MJ, Euler Z, Schweighardt B, Wrin T, Schuitemaker H.

AIDS. 2009 Nov 27;23(18):2405-14. doi: 10.1097/QAD.0b013e32833243e7.

PMID:
19770692
50.

Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.

Bunnik EM, van Gils MJ, Lobbrecht MS, Pisas L, van Nuenen AC, Schuitemaker H.

Virology. 2009 Aug 1;390(2):348-55. doi: 10.1016/j.virol.2009.05.028. Epub 2009 Jun 17.

Supplemental Content

Loading ...
Support Center